Disruption of Latent HIV in Vivo During the Clearance of Actinic Keratosis by Ingenol Mebutate

JCI insight - United States
doi 10.1172/jci.insight.126027
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

American Society for Clinical Investigation

Related search

Ingenol Mebutate Treatment in Actinic Keratosis – Clinical Effectiveness and Potential Side Effects

Postepy Dermatologii I Alergologii
DermatologyAllergyImmunology
2019English

The Role of Ingenol Mebutate in the Treatment of Actinic Keratoses

Dermatology and Therapy
Dermatology
2012English

Ablative Fractional Laser Improves Treatment of Actinic Keratoses With Ingenol Mebutate

European Journal of Inflammation
AllergyImmunology
2016English

Ingenol Mebutate: An Emerging Therapy in the Treatment of Actinic Keratoses

Current Dermatology Reports
Dermatology
2013English

Field Cancerization Therapy With Ingenol Mebutate Contributes to Restoring Skin-Metabolism to Normal-State in Patients With Actinic Keratosis: A Metabolomic Analysis

Scientific Reports
Multidisciplinary
2019English

Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate

PLoS ONE
Multidisciplinary
2016English

Efficacy and Safety of Ingenol Mebutate in Patients With Actinic Keratosis on Face and Scalp: Subgroup Analysis of Two Vehicle-Controlled Trials According to Age (<65 and ≥65 Years)

SKIN The Journal of Cutaneous Medicine
2019English

Insight Into the Management of Actinic Keratosis

British Journal of Dermatology
DermatologyMedicine
2019English

In Vivo Disruption of Latent HSV by Designer Endonuclease Therapy

JCI insight
Medicine
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy